CADTH COMMON DRUG REVIEW

Clinical Review Report

GENERIC DRUG NAME (BRAND NAME)
(Manufacturer)
Indication: Text

Service Line: CADTH Common Drug Review
Version: Draft - Confidential
Publication Date: TBC
Report Length: 22 Pages
Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners’ own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada’s federal, provincial, or territorial governments or any third party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user’s own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada’s health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
Table of Contents

List of Tables .................................................................................................................. 5
List of Figures .................................................................................................................... 5
Abbreviations .................................................................................................................... 6
Executive Summary .......................................................................................................... 7
Introduction ....................................................................................................................... 8
  Disease Prevalence and Incidence ................................................................................. 8
  Standards of Therapy ..................................................................................................... 8
  Drug under Review ........................................................................................................ 8
Stakeholder Input ............................................................................................................. 9
  Patient Group Input ....................................................................................................... 9
  Clinician Input ............................................................................................................... 9
Literature Search ............................................................................................................. 10
  Objectives ..................................................................................................................... 10
  Methods ........................................................................................................................ 10
  Findings from the Literature ......................................................................................... 11
Pivotal Studies and Randomized Controlled Trials ......................................................... 13
  Description of studies .................................................................................................. 13
  Populations ................................................................................................................... 13
  Interventions ................................................................................................................. 13
  Outcomes ...................................................................................................................... 13
  Statistical analysis ....................................................................................................... 13
  Patient Disposition ....................................................................................................... 13
  Exposure to study treatments ...................................................................................... 13
  Clinical Effectiveness ................................................................................................. 13
  Clinical Harms .............................................................................................................. 13
  Critical Appraisal ......................................................................................................... 13
Non-Randomized Studies ............................................................................................... 14
  Description of studies ................................................................................................. 14
  Populations ................................................................................................................... 14
  Interventions ................................................................................................................. 14
  Outcomes ...................................................................................................................... 14
  Statistical analysis ....................................................................................................... 14
  Patient Disposition ....................................................................................................... 14
  Exposure to study treatments ...................................................................................... 14
  Clinical Effectiveness ................................................................................................. 14
List of Tables

List of Figures
Abbreviations
## Executive Summary

<table>
<thead>
<tr>
<th>Drug</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Indication</td>
<td></td>
</tr>
<tr>
<td>Reimbursement Request</td>
<td></td>
</tr>
<tr>
<td>Dosage form(s)</td>
<td></td>
</tr>
<tr>
<td>NOC date</td>
<td></td>
</tr>
<tr>
<td>Manufacturer</td>
<td></td>
</tr>
</tbody>
</table>
Introduction

Disease Prevalence and Incidence

Standards of Therapy

Drug under Review
Stakeholder Input

Patient Group Input

Clinician Input
Literature Search

Objectives

Methods

Table 1: Inclusion criteria for the systematic review

<table>
<thead>
<tr>
<th>Patient Population</th>
<th>Intervention</th>
<th>Comparators</th>
<th>Outcomes</th>
<th>Study Design</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

.
Findings from the Literature

Figure 1: Flow Diagram for Inclusion and Exclusion of Studies

- N Citations identified in literature search
- N Potentially relevant reports from other sources
- N Potentially relevant reports identified and screened
- N Total potentially relevant reports identified and screened
- N Reports excluded
- N Reports included
  Presenting data from N unique studies
Table 2: Details of Included Studies

<table>
<thead>
<tr>
<th>Study Name</th>
<th>Study Name</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Designs &amp; Populations</strong></td>
<td></td>
</tr>
<tr>
<td>Study Design</td>
<td></td>
</tr>
<tr>
<td>Locations</td>
<td></td>
</tr>
<tr>
<td>Randomized (N)</td>
<td></td>
</tr>
<tr>
<td>Inclusion Criteria</td>
<td></td>
</tr>
<tr>
<td>Exclusion Criteria</td>
<td></td>
</tr>
<tr>
<td><strong>Drugs</strong></td>
<td></td>
</tr>
<tr>
<td>Intervention</td>
<td></td>
</tr>
<tr>
<td>Comparator(s)</td>
<td></td>
</tr>
<tr>
<td><strong>Duration</strong></td>
<td></td>
</tr>
<tr>
<td>Phase</td>
<td></td>
</tr>
<tr>
<td>Run-in</td>
<td></td>
</tr>
<tr>
<td>Double-blind</td>
<td></td>
</tr>
<tr>
<td>Follow-up</td>
<td></td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
<td></td>
</tr>
<tr>
<td>Primary End Point</td>
<td></td>
</tr>
<tr>
<td>Other End Points</td>
<td></td>
</tr>
<tr>
<td><strong>Notes</strong></td>
<td></td>
</tr>
<tr>
<td>Publications</td>
<td></td>
</tr>
</tbody>
</table>
Pivotal Studies and Randomized Controlled Trials

Description of studies

Populations

Interventions

Outcomes

Statistical analysis

Patient Disposition

Exposure to study treatments

Clinical Effectiveness

Clinical Harms

Critical Appraisal

Internal validity

External validity
Non-Randomized Studies

Description of studies

Populations

Interventions

Outcomes

Statistical analysis

Patient Disposition

Exposure to study treatments

Clinical Effectiveness

Clinical Harms

Critical Appraisal

Internal validity

External validity
Indirect Comparisons

Description of Indirect Comparison(s)

Methods

Study Eligibility and Selection Process

Data extraction

Quality assessment of included studies

Comparators

Outcomes

Evidence network

Statistical analysis

Results

Critical Appraisal of Indirect Comparisons

Summary and Conclusions
Discussion

Summary of Available Evidence

Interpretation of Results

Efficacy

Harms

Other Considerations

Conclusions
Appendix 1: Literature Search Strategy
Appendix 2: Excluded Studies
Appendix 3: Detailed Outcome Data
Appendix 4: Validity of Outcome Measures
Appendix 5: Summary of Other Studies
References